Impacts of Neoadjuvant Hormonal Therapy Prior to Robot-Assisted Radical Prostatectomy on Postoperative Hormonal- and Sexual-Related Quality of Life - Assessment by Patient-Reported Questionnaire.

Content Provider	Europe PMC
Author	Ogawa, Soichiro Hasegawa, Akihisa Makabe, Shunta Onagi, Akifumi Matsuoka, Kanako Kayama, Emina Koguchi, Tomoyuki Hata, Junya Sato, Yuichi Akaihata, Hidenori Kataoka, Masao Haga, Nobuhiro Kojima, Yoshiyuki
Copyright Year	2022
Abstract	PurposeNeoadjuvant hormonal therapy (HT) before radical prostatectomy (RP) is not recommended by current guidelines in terms of oncological outcomes. Despite this, neoadjuvant HT is sometimes conducted before RP for a small proportion of patients in clinical practice. This study evaluated the impacts of neoadjuvant HT on hormonal- and sexual-related quality of life (QOL) among patients who underwent robot-assisted RP (RARP).Materials and MethodsParticipants comprised 470 patients divided into a non-neoadjuvant HT group (n = 408) and a neoadjuvant HT group (n = 62). Hormonal- and sexual-related QOL were measured using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.ResultsHormonal summary scores at 6 and 9 months, function scores before and 3, 6, and 9 months and bother score at 6 months after RARP were significantly lower in the neoadjuvant HT group than in the non-neoadjuvant HT group. Sexual function scores were decreased in the neoadjuvant HT group compared to the non-neoadjuvant HT group before and 6 months after RARP. In the neoadjuvant HT group, sexual function at 3 months after RARP was significantly worse in patients with >5 months of neoadjuvant HT than in patients with ≤5 months of neoadjuvant HT. Conversely, sexual bother at 3 months after RARP was significantly worse in patients with ≤5 months of neoadjuvant HT than in patients with >5 months of neoadjuvant HT.ConclusionVintage neoadjuvant HT prior to RARP should not be recommended due to not only oncological outcomes, but also the impacts on postoperative hormonal- and sexual-related QOL.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8865904&blobtype=pdf
Page Count	10
Journal	Research and Reports in Urology [Res Rep Urol]
Volume Number	14
PubMed Central reference number	PMC8865904
PubMed reference number	35223660
e-ISSN	22532447
DOI	10.2147/rru.s342063
Language	English
Publisher	Dove
Publisher Date	2022-02-19
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2022 Ogawa et al.
Subject Keyword	androgen deprivation therapy Expanded Prostate Cancer Index Composite quality of life hormonal therapy neoadjuvant robot-assisted radical prostatectomy
Content Type	Text
Resource Type	Article
Subject	Urology